Print Bookmark Email

Partners in Discovery

PID 2014 thumbNew CF Therapies
Fall 2014
In this issue, transitioning to adult care, a perspective on new CF therapies, and the push to clarify CF-related mutations.
PID Fall 2012 imageModifying Disease
Fall 2012
Modifying Disease: By developing compounds that push proteins to the surface of the lungs and then turn them on, researchers aim to correct the salt and water imbalance that causes cystic fibrosis.
Spring 2011Understanding Inflammation
Spring 2011
Understanding Inflammation: Researcher Neeraj Vij uncovers new clues regarding airway inflammation in CF
Winter 2010CF and Diabetes
Winter 2010
CF and Diabetes: Researcher Scott Blackman's search for modifier genes to tailor treatment.
PID Spring 09 detailAlternative Chloride Channels
Spring 2009
Alternative Chloride Channels: CFTR isn’t the only kid on the block when it comes to chloride channels. ClC-2, pulmonologist Pam Zeitlin is finding, may provide a parallel pathway for chloride secretion.
PID Fall 08 imgCFTR-Targeted Drugs
Fall 2008
CFTR-targeted drugs lead a diverse pack of therapies to improve quality of life, extend survival and find a cure for CF patients.
PID winter 08 imgThe Jigsaw Puzzle of CF
Winter 2008
What is it in the genes and environment that really makes a difference? Why does one cystic fibrosis patient have only mild lung disease while another patient—with the same CFTR mutations—suffers severe lung disease? Are genes other than CFTR responsible for these variations? Or is the environment the cause?
imgPartnersinDiscoveryStudying the Science of Resistance
Summer 2007
Pseudomonas aeruginosa is a nasty bug, infecting nearly 80 percent of all CF patients. And its success lies in part to its reputation for resisting many common antibiotics thrown at it. In fact, although immediate treatment with antibiotics can clear the infection, in many cases the bacteria adapt and establish permanent colonies in the lungs, increasing sputum production and decreasing lung function.
Fall2006-PIDAdvancing CF Knowledge
Fall 2006
A distinct advantage to being a patient of The Johns Hopkins Cystic Fibrosis Center is that the doctors you see regularly are contributing significantly to the understanding and management of cystic fibrosis worldwide.